Clinical Trials at the Inflection Point: What Sponsors Must Solve Next
The next 18 to 24 months will test whether sponsors can build trials that are easier to run without weakening the evidence.
Leading clinical development teams from Astellas, Regeneron, Genentech, Roche, Bayer, Eisai, and Takeda are rethinking site strategy, patient access, protocol design, real-world evidence, and AI governance. Discover how in the latest whitepaper: Clinical Trials at the Inflection Point: What Sponsors Must Solve Next.
Understand their thinking - Download your free copy today >>>
Find out what leading clinical development teams are doing across five critical areas:
- Site Strategy: building trust and operational conduct that earns sponsor of choice status
- Patient Recruitment: designing access into trials before recruitment begins
- Protocol Design: distinguishing essential complexity from avoidable complexity
- Evidence Generation: using real-world data, Bayesian methods and adaptive designs with regulatory rigour
- AI and Digital Enablement: moving from pilots to governed, auditable systems
Hear from the people currently solving these issues - Download the whitepaper and take their thinking back to your team.>>>
Please feel free to get in contact if you have any questions or feedback.
Kind regards,
Benchmark your approach – Download the report and see how industry leaders are rethinking future clinical development
By submitting this form, you acknowledge the Thomson Reuters group of companies will process your personal information as described in our Privacy Statement
which explains how we collect, use, store, and disclose your personal information, the consequences if you do
not provide this information, and the way in which you
can access and correct your personal information or submit a complaint.
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.